Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 23:17:2043-2052.
doi: 10.2147/IDR.S460513. eCollection 2024.

Value Evaluation of Quantitative Aspergillus fumigatus-Specific IgG Antibody Test in the Diagnosis of Non-neutropenic Invasive Pulmonary Aspergillosis

Affiliations

Value Evaluation of Quantitative Aspergillus fumigatus-Specific IgG Antibody Test in the Diagnosis of Non-neutropenic Invasive Pulmonary Aspergillosis

Lingyan Sheng et al. Infect Drug Resist. .

Abstract

Background: The role of Aspergillus-specific IgG antibody test in the diagnosis of non-neutropenic invasive pulmonary aspergillosis (IPA) is still uncertain, and related studies are also limited.

Purpose: This study aims to evaluate the quantitative test value of Aspergillus fumigatus-specific IgG antibody in non-neutropenic IPA, which could provide additional evidence for related clinical diagnosis.

Methods: This prospective study collected clinical data of suspected IPA patients from January, 2020 to December, 2022, and patients were divided into two groups, IPA and non-IPA. The study analyzed clinical characteristics and diagnostic value of Aspergillus-specific IgG antibody test, using the receiver operating characteristic (ROC) curve to evaluate diagnostic efficacy.

Results: The study enrolled 59 IPA cases and 68 non-IPA cases, the average admission age of IPA group was 63.2±9.6 (33-79), and the gender ratio (male:female) of IPA group was 42:17. The proportion of patients with history of smoking and COPD were higher in IPA group (59.3% vs 39.7%, P=0.027; 33.9% vs 14.7%, P =0.011, respectively). The level of Aspergillus fumigatus-specific IgG antibody in IPA group was significantly higher than non-IPA group (202.1±167.0 vs 62.6±58.0, P<0.001). The area under the ROC curve was 0.799 (95%CI: 0.718, 0.865 P<0.001), and the cut-off with best diagnostic efficacy was 91 AU/mL.

Conclusion: Immunological test plays an important role in the diagnosis of pulmonary aspergillosis, and Aspergillus-specific IgG antibody test has the good diagnostic value in non-neutropenic IPA.

Keywords: Aspergillus; IgG; diagnosis; invasive pulmonary aspergillosis; non-neutropenic.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The flow chart of the study. The criteria of possible IPA: (1) Patients’ age ≥18; (2) immune insufficiency (such as congenital immunodeficiency, long-term glucocorticoid treatment (glucocorticoid treatment time ≥3 weeks in the past 60 days), long-term immunosuppressive therapy after solid organ transplantation, radiotherapy and chemotherapy for malignant tumors, etc) or others with emerging risk factors of IPA, such as end-stage COPD, liver cirrhosis, etc; (3) The time for appearance of suspected clinical symptoms or abnormal imaging manifestations of IPA was ≤1 month; (4) abnormal infiltrative manifestations in pulmonary CT images. On the basis of the possible IPA, proven IPA criteria should also meet: histopathological evidence or positive culture result from sterile environment (excluding BALF), probable IPA criteria should meet: mycologic evidence such as GM test, positive culture result (qualified specimen from sputum, BALF, bronchial brush), Aspergillus PCR, etc.
Figure 2
Figure 2
(A) The level of Aspergillus fumigatus-specific IgG antibody in IPA and non-IPA patients. (B) The level of A. fumigatus-specific IgG antibody in possible, probable and proven IPA patients. ***p < 0.001.
Figure 3
Figure 3
The ROC curve of Aspergillus fumigatus-specific IgG antibody test in the diagnosis of IPA.

Similar articles

Cited by

References

    1. Larkin PMK, Multani A, Beaird OE, et al. A collaborative tale of diagnosing and treating chronic pulmonary aspergillosis, from the perspectives of clinical microbiologists, surgical pathologists, and infectious disease clinicians. J Fungi. 2020;6(3). doi:10.3390/jof6030106 - DOI - PMC - PubMed
    1. Samson RA, Visagie CM, Houbraken J, et al. Phylogeny, identification and nomenclature of the genus Aspergillus. Stud Mycol. 2014;78:141–173. doi:10.1016/j.simyco.2014.07.004 - DOI - PMC - PubMed
    1. Hospenthal DR, Kwon-Chung KJ, Bennett JE. Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol. 1998;36(3):165–168. - PubMed
    1. Richardson MD, Page ID. Aspergillus serology: have we arrived yet? Med Mycol. 2017;55(1):48–55. doi:10.1093/mmy/myw116 - DOI - PubMed
    1. Strieter RM, Belperio JA, Keane MP. Cytokines in innate host defense in the lung. J Clin Investig. 2002;109(6):699–705. doi:10.1172/jci15277 - DOI - PMC - PubMed